

OWC Pharma appoints Dr Oron Yacoby Zeevi as CSO

February 21, 2018 | News

Dr Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry.



Israel based OWC Pharmaceutical Research Corp., a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, has announced the appointment of Dr Oron Yacoby Zeevi as its Chief Scientific Officer (CSO).

Dr Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry. She joined Neuroderm, a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders in 2008 as the Vice President of Research and was promoted to the position of VP R&D in 2010. From October 2016 until her recent departure, she served as Chief Scientific Officer. Neuroderm was sold to Mitsubishi Tanabe Pharma for \$1.1 billion in July 2017.

Zeevi is the inventor of over 50 issued patents and pending patents. Her expertise lies in industry-oriented innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D proof of concept, intellectual property development, chemistry and manufacturing controls (CMC), early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs.

She earned her Ph.D. in microbiology and immunology from Ben Gurion University in Be'er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine from the Hebrew University of Jerusalem.